Is there any vindication for low dose nonselective β-blocker medication in patients with liver cirrhosis?

• Published in: Clinical and molecular hepatology 2012, 18(2), , pp.203-212
• Main Authors: Kim, Tae Wan, Kim, Hong Joo, Chon, Chang Uk, Won, Hyun Sun, Park, Jung Ho, Park, Dong Il, Cho, Yong Kyun, Sohn, Chong Il, Jeon, Woo Kyu, Kim, Byung Ik
• Format: Article
• Language: English
• Subjects: Adrenergic beta-Antagonists - therapeutic use; Adult; Age; Aged; Alcohol Drinking; Beta blockers; Carcinoma, Hepatocellular - complications; Carcinoma, Hepatocellular - diagnosis; Child-Turcotte-Pugh; Creatinine; Diabetes; Disease prevention; Drug dosages; Enrollments; Esophagus; Female; Follow-Up Studies; Heart rate; Hepatitis B; Hepatitis C; Humans; Hypertension; Kaplan-Meier Estimate; Kidney diseases; Kidney Failure, Chronic - complications; Kidney Failure, Chronic - diagnosis; Liver cancer; Liver cirrhosis; Liver Cirrhosis - complications; Liver Cirrhosis - drug therapy; Liver Cirrhosis - mortality; Liver diseases; Liver Neoplasms - complications; Liver Neoplasms - diagnosis; Male; Middle Aged; Mortality; Nonselective β-blockers; Original; Overall survival; Predictive Value of Tests; Proportional Hazards Models; Propranolol - therapeutic use; Retrospective Studies; Severity of Illness Index; 내과학
• ISSN: 2287-2728; 2287-285X
• DOI: 10.3350/cmh.2012.18.2.203

Nonselective β-blockers (NSBBs), such as propranolol, reportedly exert a pleiotropic effect in liver cirrhosis. A previous report suggested that survival was higher in patients receiving adjusted doses of NSBBs than in ligation patients. This study investigated whether low-dose NSBB medication has beneficial effects in patients with liver cirrhosis, especially in terms of overall survival. We retrospectively studied 273 cirrhotic patients (199 males; age 53.6±10.2 years, mean±SD) who visited our institution between March 2003 and December 2007; follow-up data were collected until June 2011. Among them, 138 patients were given a low-dose NSBB (BB group: propranolol, 20-60 mg/day), and the remaining 135 patients were not given an NSBB (NBB group). Both groups were stratified randomly according to Child-Turcotte-Pugh (CTP) classification and age. The causes of liver cirrhosis were alcohol (n=109, 39.9%), hepatitis B virus (n=125, 45.8%), hepatitis C virus (n=20, 7.3%), and cryptogenic (n=19, 7.0%). The CTP classes were distributed as follows: A, n=116, 42.5%; B, n=126, 46.2%; and C, n=31, 11.4%. Neither the overall survival (P=0.133) nor the hepatocellular carcinoma (HCC)-free survival (P=0.910) differed significantly between the BB and NBB groups [probability of overall survival at 4 years: 75.1% (95% CI=67.7-82.5%) and 81.2% (95% CI=74.4-88.0%), respectively; P=0.236]. In addition, the delta CTP score did not differ significantly between the two groups. Use of low-dose NSBB medication in patients with liver cirrhosis is not indicated in terms of overall and HCC-free survival.